



Subject: Drug, Device or Biologic (Off-Label Use)*

Effective Date: August 1, 1994

Department(s): Utilization Management

Policy: All requests for certification of coverage for off label use of a FDA approved drug, device or biologic must be reviewed by QualCare's Utilization Management Medical Director and/or a Medical Advisor in the specialty area in question for usage.

Procedure:

- A. The use of drugs, devices, or biologics not approved by the FDA will **NOT** be reimbursed.
- B. A physician requesting certification for off-label use of a drug, device or biologic must submit the following information to QualCare's Utilization Management Department:
 - 1. A complete past and present history regarding prior course of treatment that addresses failure of treatment of this individual with interventions approved by the FDA or other agencies for the individual's diagnosis.
 - 2. Documentation, including but not limited to peer-reviewed articles, regarding the success or failure of the drug, device or biologic for the intended off-label use.
 - 3. Acknowledgement that the patient is aware of the off-label use and any known potential side effects.

C. Off-label use of a drug, device, or biologic that is not supported by a satisfactory body of peer-reviewed literature will be denied as experimental, investigational, and unproven.

References

Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. *J Clin Pharm Ther.* 2017;42(3):251-258(Jun)

“Off-Label” and Investigational Use of Marketed Drugs, Biologics, and Medical Devices-Information Sheet. Accessed at FDA.gov/regulatoryinformation/guidances/ucm126486.htm, last updated 1/25/16.

“Off-Label” and Investigational Use of Marketed Drugs, Biologics, and Medical Devices-Information Sheet. Accessed at FDA.gov/regulatoryinformation/guidances/ucm126486.htm, last updated 6/25/14.

Largent EA, Miller FG, Pearson SD. Going Off-label Without Venturing Off-Course. *Arch Intern Med* 2009; 169(9):1745-1747 (Oct 26)

Dresser R, Frader J. Off-label prescribing: A call for heightened professional and government oversight. *J Law Med Ethics* 2009; 37(3):476-486 (Fall)

Gallic MR. Controlling Off-Label medication Use. *Ann Intern Med*2009;150(5):344-347 (Feb 16)

Tanbark A. From off-label prescribing towards a new FDA. *Med Hypotheses.* 2009;72(1):11-13 (Jan)

Joseph JN, Deaton D, Ehsan H, et al. Enforcement related to off-label marketing and use of drugs and devices: Where have we been and where are we going? *J Health Life Sci Law* 2009;2(2):73-108 (Jan)

Rao SV, Califf RM, Kramer JM, *et al.* Postmarket evaluation of breakthrough technologies. *Am Heart J* 2008;156(2):201-208 (Aug)

-----Guidance for off-label use of drugs. *Lancet Neurol* 2008;7(4):285 (Apr)

Paolucci P, Pritchard Jones K, delCarmen M, et al. Challenges in prescribing drugs for children with cancer. *Lancet Oncol* 2008;(9):176-183 (Feb)

US Food and Drug Administration. Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices. Draft Guidance. February 2008

Parrish R II, Sternberg P Jr. Does “Off-Label” Mean Off Limits for Patient Care? *Am J Ophthalmol* 2007;144(5):853-855 (May)

Smith DI, Swamy PM, Heffernan MP. Off-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (part 1 of 2). *J Am Acad Dermatol* 2007;56(1):e1-e54 (Jan)

Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). *J Am Acad Dermatol* 2007;56(1):e55-e79 (Jan)

Rosenfeld PH. Intravitreal Avastin: The Low Cost Alternative to Lucentis? *Am J Ophthalmol* 2007;142(1):141-143 (Jul)

Califf RM. Evaluation of diagnostic imaging technologies and therapeutics devices: Better information for better decision: Proceedings of a multidisciplinary workshop. *Am Heart J* 2006;151(6):50-58 (Jun)

Murphy S, Roberts R. “Black box” 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk *J Allergy Clin Immunol* 2006;117(1):34-39 (Jan)

Chang NS, Simone AF, Schultheis LW. From the FDA: What’s in a Label? A Guide for the Anesthesia Practitioner. *Anesthesiology* 2005;103(1):179-185 (Jul)

Bennett WM. Off-Label Use of Approved Drugs: Therapeutic Opportunity and Challenges *J Am Soc Nephrol* 2004;15(3):831-831 (Mar)

O’Shea JC, Kramer JM, Califf RM, et al. Results of expert meetings: Part I: Identifying holes in the safety net. *Am Heart J* 2004;147(6):977-984 (Jun)

Peterson ED, Hirshfeld JW, Ferguson TB, et al. Results of expert meetings: Part II: Sealing holes in the safety net. *Am Heart J* 2004;147(6):985-990 (Jun)

Maisel WH. Medical Device Regulation: An Introduction for the Practicing Physician. *Ann Int Med* 2004;140(4):296-302

Nelson DB, Block KP, Bosco JJ, et al. Guidelines: Medical device evaluation by the Food and Drug Administration (FDA): November 2000. *Gastrointest Endosc* 2001;53(7):880-884

----Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices—FDA. Final Rule. *Fed Regist* 1998;63(224):64556-64588 (Nov 20)

Approved By/Date: QM Committee 08/01/94

Revised By/Date: BFisher, MD 05/10/06

Approved By/Date: QM Committee 05/23/06

Revised By/Date: BFisher, MD 11/18/06

Approved By/Date: QM Committee 12/12/06

CONFIDENTIAL-NOT FOR DISTRIBUTION OUTSIDE OF QUALCARE

Reviewed without Revision By/Date: BFisher, MD 10/06/08
Approved By/Date: QM Committee 12/09/08
Revised By/Date: BFisher, MD 07/15/10
Approved By/Date: QM Committee 07/27/10
Reviewed without Revision By/Date: MMcNeil, MD 05/21/12
Approved By/Date: QM Committee 06/12/12
Reviewed w/o Revision By/Date: MMcNeil, MD 06/30/14
Approved By: QM Committee: 07/22/14
Reviewed w/o Revision By/Date: MMcNeil, MD 11/16/16
Approved By/Date: QM Committee 12/13/16
Reviewed w/o Revision By/Date: MMcNeil, MD 06/06/18
Approved By/Date: QM Committee 06/19/18

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.